Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 4 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Papillomavirus Infections 9 Uterine Cervical Neoplasms 4 Neuroendocrine Tumors 4 Autoimmune Diseases 3 Prostatic Neoplasms 2 Neoplasms 2 Abortion, Spontaneous 2 Recurrence 1 Ovarian Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neuroblastoma 1 Neoplastic Cells, Circulating 1 Neoplasm Metastasis 1 Myasthenia Gravis 1 Lymphohistiocytosis, Hemophagocytic 1 Lung Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

Paclitaxel 113 Carboplatin 99 Bevacizumab 59 pembrolizumab 56 liposomal doxorubicin 56 Gemcitabine 42 olaparib 39 Topotecan 33 niraparib 29 Nivolumab 21 Cisplatin 21 Doxorubicin 17 Cyclophosphamide 17 1-dodecylpyridoxal 16 Drug Therapy 15 Docetaxel 15 avelumab 13 Fulvestrant 11 oregovomab 10 Oxaliplatin 10 rucaparib 9 fludarabine 9 Injections 9 Fluorouracil 9 veliparib 8 mirvetuximab soravtansine 8 atezolizumab 8 Cetuximab 8 fluzoparib 7 cemiplimab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Neoplasms × Data Collection × Clear all

NCT02262273 2017-03-01

OSCA

AstraZeneca

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡